Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

80P - The analysis of ROS1 fusions characteristics in Chinese solid tumor patients


10 Sep 2022


Poster session 01


Pathology/Molecular Biology

Tumour Site


Yujing Lin


Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037


Y. Lin1, Y. Zhao2, D. Guo2, G. Lu2, W. Deng3, F. Bu4, R. Ding4

Author affiliations

  • 1 Pathology Department, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000 - Zhuhai/CN
  • 2 The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., 210042 - Nanjing/CN
  • 3 Bioinformatics Department, Jiangsu Simcere Diagnostics Co., Ltd., 210042 - Nanjing/CN
  • 4 Operations Department, Jiangsu Simcere Diagnostics Co., Ltd, 210042 - Nanjing/CN

Abstract 80P


Based on the approvals of crizotinib and entrectinib by the Food and Drug Administration for the treatment of ROS1-positive non-small lung cancer, we sought to analysis of ROS1 fusions characteristics in Chinese solid tumor patients to explore the possibility of therapeutic intervention in solid tumors.


In this study, we retrospectively analyzed ROS1 fusion using next-generation sequencing(NGS). For the purposes of this study we excluded any ROS1 fusions where the ROS1 kinase domain wasn't predicted to be preserved. From May 2019 to April 2022, 50543 patients were detected.


A total of 296 unique cases (92.9% (275/296) lung cancer and 7.1% (21/296) non-lung cancer with ROS1 fusions were identified. The non-lung cancer cohort consisted up mainly brain tumors (33.3%, 7/21), gastric tumors (14.3%, 3/21), colorectal tumors (9.5%, 2/21), melanoma (9.5%, 2/21) and biliary tumors (9.5%, 2/21). The top five fusion partners identified in the lung cancer cohort were CD74 (43.1%), EZR (23.1%), SDC4(13.0%), SLC34A2 (5.0%), and TPM3 (2.5%). On the other hand, the most common fusion partners were GOPC(30.4%)and DST (8.6%) in the non lung cancer cohort. Nine novel partners, DST, CABYR, CRYBG1, ETV1, MBNL2, MICAL2, UNC13A,CTNNA1 and PPP1R10 were identified across both cohorts of patients. Interestingly, in the lung cancer ROS1 fusion positive cohort, the breakpoints most frequently occurred in ROS1 introns 33, 32, and 31, while in the non-lung cancer ROS1 fusion-positive cohort, more than half of the breakpoints occurred in ROS1 intron 34. 79 patients in the lung cancer ROS1 fusion-positive cohort and 14 patients in the non-lung cancer ROS1 fusion-positive cohort could be evaluated for concurrent mutations and microsatellite instability (MSI) status. Overall, fewer other diver mutations was found in both cohorts of patients and no cases had an MSI-H status.


ROS1 fusions were detected in 0.59%(296/50543) of Chinese solid tumor patients. 92.9% of ROS1 fusion-positive cases were diagnosed with lung cancer and 7.1% were diagnosed with non-lung cancer. ROS1 fusion is an important driver genomic alteration in both the lung cancer and non-lung cancer cohorts. ROS1 targeted therapies should be further explored in non-lung cancer in clinical studies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.